Publications 2010
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
J Clin Oncol. 2010 Mar 1;28(7):1247-53
, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van't Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbaue H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van't Veer L, Easton DF, Spellman PT, Martin S, Barker AD, Chin L, Collins FS, Compton CC, Ferguson ML, Gerhard DS, Getz G, Gunter C, Guttmacher A, Guyer M, Hayes DN, Lander ES, Ozenberger B, Penny R, Peterson J, Sander C, Shaw KM, Speed TP, Spellman PT, Vockley JG, Wheeler DA, Wilson RK, Hudson TJ, Chin L, Knoppers BM, Lander ES, Lichter P, Stein LD, Stratton MR, Anderson W, Barker AD, Bell C, Bobrow M, Burke W, Collins FS, Compton CC, DePinho RA, Easton DF, Futreal PA, Gerhard DS, Green AR, Guyer M, Hamilton SR, Hubbard TJ, Kallioniemi OP, Kennedy KL, Ley TJ, Liu ET, Lu Y, Majumder P, Marra M, Ozenberger B, Peterson J, Schafer AJ, Spellman PT, Stunnenberg HG, Wainwright BJ, Wilson RK, Yang H
International network of cancer genome projects.
Nature. 2010 Apr 15;464(7291):993-8
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL, , Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B, , Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M, , Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S, , Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L, , Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay M, Vénat-Bouvet L, , Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D, , Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TV, Jønson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X, , Platte R, Chenevix-Trench G, Easton DF,
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Cancer Res. 2010 Dec 1;70(23):9742-54
Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
Clin Cancer Res. 2010 Jan 1;16(1):203-11
Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Eur J Cancer. 2010 Feb;46(3):517-25
Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Bojesen SE, Nordestgaard BG, Flyger H, Milne RL, Arias JI, Menéndez P, Benítez J, Chang-Claude J, Hein R, Wang-Gohrke S, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Margolin S, Mannermaa A, Kosma VM, Kataja V, , Beesley J, Chen X, Chenevix-Trench G, Couch FJ, Olson JE, Fredericksen ZS, Wang X, Giles GG, Severi G, Baglietto L, Southey MC, Devilee P, Tollenaar RA, Seynaeve C, García-Closas M, Lissowska J, Sherman ME, Bolton KL, Hall P, Czene K, Cox A, Brock IW, Elliott GC, Reed MW, Greenberg D, Anton-Culver H, Ziogas A, Humphreys M, Easton DF, Caporaso NE, Pharoah PD
Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival.
J Natl Cancer Inst. 2010 May 5;102(9):650-62
Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, Uckert W, Song JY, Haanen JB, Schumacher TN
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.
Nat Med. 2010 May;16(5):565-70, 1p following 570
Boere IA, Hamberg P, Sleijfer S
It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
Cancer Sci. 2010 Jan;101(1):7-15
Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
J Clin Oncol. 2010 May 10;28(14):2460-6
Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Br J Pharmacol. 2010 Feb;159(4):898-908
Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S, Debets R
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.
Expert Opin Biol Ther. 2010 Apr;10(4):547-62
Damen TH, Timman R, Kunst EH, Gopie JP, Bresser PJ, Seynaeve C, Menke-Pluijmers MB, Mureau MA, Hofer SO, Tibben A
High satisfaction rates in women after DIEP flap breast reconstruction.
J Plast Reconstr Aesthet Surg. 2010 Jan;63(1):93-100
de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
J Pharm Biomed Anal. 2010 Mar 11;51(4):934-41
de Graaf MT, de Beukelaar JW, Haasnoot GW, Levering WH, Rogemond V, Didelot A, Honnorat J, Gratama JW, Smitt PA
HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.
J Neuroimmunol. 2010 Sep 14;226(1-2):147-9
de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, den Hollander MA, van der Biessen D, Lam MH, Verweij J, Gelderblom H
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
Eur J Cancer. 2010 Nov;46(16):3016-21
De Vos FY, Middelburg TA, Seynaeve C, de Jonge MJ
Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy.
J Infect Chemother. 2010 Jan 7;
Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
BMC Cancer. 2010;10:247
Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C
Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7
Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.
Clin Cancer Res. 2010 Aug 15;16(16):4198-206
Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LC, van Agthoven T
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
Br J Cancer. 2010 Oct 12;103(8):1284-91
Govers C, Sebestyén Z, Coccoris M, Willemsen RA, Debets R
T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing.
Trends Mol Med. 2010 Feb;16(2):77-87
Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, Forman SJ, Gaal K, Bray KR, Gasior GH, Boyce CS, Sullivan LA, Southwick PC
Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study.
Blood. 2010 Sep 9;116(10):1655-62
Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Eur J Cancer. 2010 Jul;46(11):2010-9
Hamberg P, Ratain MJ, Lesaffre E, Verweij J
Dose-escalation models for combination phase I trials in oncology.
Eur J Cancer. 2010 Nov;46(16):2870-8
Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Br J Cancer. 2010 Jun 8;102(12):1699-706
Hamberg P, Verweij J, Sleijfer S
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Oncologist. 2010;15(6):539-47
Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium
Development of adoptive cell therapy for cancer: a clinical perspective.
Hum Gene Ther. 2010 Jun;21(6):665-72
Heemskerk-Gerritsen BA, Kriege M, Seynaeve C
Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers.
JAMA. 2010 Dec 22;304(24):2695; author reply 2695-6
Helleman J, Jansen MP, Burger C, van der Burg ME, Berns EM
Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.
Int J Biochem Cell Biol. 2010 Jan;42(1):25-30
Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
Gynecol Oncol. 2010 May;117(2):170-6
Hollestelle A, Wasielewski M, Martens JW, Schutte M
Discovering moderate-risk breast cancer susceptibility genes.
Curr Opin Genet Dev. 2010 Jun;20(3):268-76
Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S
Gene expression-based classification of non-small cell lung carcinomas and survival prediction.
PLoS One. 2010;5(4):e10312
Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P, ,
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
Lancet Oncol. 2010 Jun;11(6):561-70
Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Hypertension. 2010 Oct;56(4):675-81
Kitzen JJ, de Jonge MJ, Verweij J
Aurora kinase inhibitors.
Crit Rev Oncol Hematol. 2010 Feb;73(2):99-110
Kitzen JJ, Puozzo C, de Jonge MJ, Brandely M, Verweij J
Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
Eur J Cancer. 2010 Jan;46(2):266-9
Konings IR, de Jonge MJ, Burger H, van der Gaast A, van Beijsterveldt LE, Winkler H, Verweij J, Yuan Z, Hellemans P, Eskens FA
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
Br J Cancer. 2010 Sep 28;103(7):987-92
Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
Eur J Cancer. 2010 Dec;46(18):3200-4
Lalmahomed ZS, Kraan J, Gratama JW, Mostert B, Sleijfer S, Verhoef C
Circulating tumor cells and sample size: the more, the better.
J Clin Oncol. 2010 Jun 10;28(17):e288-9; author reply e290
Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
Br J Cancer. 2010 Sep 7;103(6):765-71
Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG
Role of Mdm4 in drug sensitivity of breast cancer cells.
Oncogene. 2010 Apr 22;29(16):2415-26
Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, Zuo Z, Loos WJ, Sparreboom A
Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.
Clin Cancer Res. 2010 Oct 1;16(19):4789-99
Li J, Humphreys K, Darabi H, Rosin G, Hannelius U, Heikkinen T, Aittomäki K, Blomqvist C, Pharoah PD, Dunning AM, Ahmed S, Hooning MJ, Hollestelle A, Oldenburg RA, Alfredsson L, Palotie A, Peltonen-Palotie L, Irwanto A, Low HQ, Teoh GH, Thalamuthu A, Kere J, D'Amato M, Easton DF, Nevanlinna H, Liu J, Czene K, Hall P
A genome-wide association scan on estrogen receptor-negative breast cancer.
Breast Cancer Res. 2010;12(6):R93
Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N, Schmitt M
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert Rev Mol Diagn. 2010 Oct;10(7):947-62
Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, Sartor C, Hogendoorn PC, Sciot R, Van Glabbeke M, Verweij J, Blay JY, Hohenberger P, Flanagan A, Dei Tos AP
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.
Histopathology. 2010 Aug;57(2):259-70
Pander J, Wessels JA, Mathijssen RH, Gelderblom H, Guchelaar HJ
Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle.
Pharmacogenomics. 2010 Jul;11(7):1011-7
Pijpe A, Manders P, Mulder RL, van Leeuwen FE, Rookus MA,
Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers.
Eur J Epidemiol. 2010 Feb;25(2):103-13
Pouw N, Treffers-Westerlaken E, Kraan J, Wittink F, ten Hagen T, Verweij J, Debets R
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
Cancer Immunol Immunother. 2010 Jun;59(6):921-31
Pouw N, Treffers-Westerlaken E, Mondino A, Lamers C, Debets R
TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Mol Immunol. 2010 Apr;47(7-8):1411-20
Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R,
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.
Oncologist. 2010;15(9):935-43
Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, Walter MA, Martens JW, Richardson AL, Giuliano AE, Cui X
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.
Cancer Res. 2010 May 15;70(10):3870-6
Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
J Clin Oncol. 2010 Dec 20;28(36):5265-73
Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, van Noord C, Visser LE, Stricker BH
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.
Pharmacogenomics. 2010 Oct;11(10):1367-75
Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, ,
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Lancet. 2010 Oct 2;376(9747):1155-63
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
J Clin Oncol. 2010 Mar 10;28(8):1294-300
Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB
Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
Crit Rev Oncol Hematol. 2010 Nov;76(2):133-41
Schilder CM, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, van Dam FS, Schagen SB
The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy.
Psychooncology. 2010 Apr;19(4):415-22
Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert Rev Mol Diagn. 2010 Nov;10(8):1051-67
Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Eur J Cancer. 2010 Aug;46(12):2206-15
Schroten C, Kraaij R, Veldhoven JL, Berrevoets CA, den Bakker MA, Ma Q, Sadelain M, Bangma CH, Willemsen RA, Debets R
T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
J Immunol Methods. 2010 Jul 31;359(1-2):11-20
Sigurdardottir KR, Haugen DF, van der Rijt CC, Sjøgren P, Harding R, Higginson IJ, Kaasa S,
Clinical priorities, barriers and solutions in end-of-life cancer care research across Europe. Report from a workshop.
Eur J Cancer. 2010 Jul;46(10):1815-22
Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Eur J Cancer. 2010 Jan;46(1):72-83
Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X, Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A, Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S, Shen CY, Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T, Sigurdsson H, Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L, Kristjansson K, Halldorsson BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA, Mayordomo JI, Foekens JA, Couch FJ, Olopade OI, Gudbjartsson DF, Thorsteinsdottir U, Rafnar T, Johannsson OT, Stefansson K
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.
PLoS Genet. 2010 Jul;6(7):e1001029
Strijbos MH, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LW, Sleijfer S
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.
Eur J Cancer. 2010 Jul;46(11):2027-35
Strijbos MH, Snijder CA, Kraan J, Lamers CH, Gratama JW, Duvekot JJ
Levels of circulating endothelial cells in normotensive and severe preeclamptic pregnancies.
Cytometry B Clin Cytom. 2010 Nov;78(6):382-6
Strijbos MH, van Krimpen BA, Debets R, Kraan J, Sleijfer S, Gratama JW, Lamers CH
mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells.
Thromb Haemost. 2010 Aug 2;104(2):318-26
Surmont V, Smit EF, de Jonge M, Aerts JG, Nackaerts K, Vernhout R, Gras J, Van Wijk A, Phernambucq EC, van Meerbeeck JP, Senan S, Kraaij CJ, Chouaki N, Praag J, van Klaveren RJ
Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.
Lung Cancer. 2010 Sep;69(3):302-6
Swart SJ, Brinkkemper T, Rietjens JA, Blanker MH, van Zuylen L, Ribbe M, Zuurmond WW, van der Heide A, Perez RS
Physicians' and nurses' experiences with continuous palliative sedation in the Netherlands.
Arch Intern Med. 2010 Jul 26;170(14):1271-4
Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, Casado A
Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.
J Natl Cancer Inst. 2010 Jul 7;102(13):982-7
Tuna M, Smid M, Zhu D, Martens JW, Amos CI
Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer.
PLoS One. 2010;5(11):e15094
Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W, Eccles D, Evans DG, , Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF
Genome-wide association study identifies five new breast cancer susceptibility loci.
Nat Genet. 2010 Jun;42(6):504-7
van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, van Agthoven TL, Sarwari R, Sleijfer S, Foekens JA, Dorssers LC
Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
Endocr Relat Cancer. 2010 Mar;17(1):215-30
van Broekhoven F, de Graaf MT, Bromberg JE, Hooijkaas H, van den Bent MJ, de Beukelaar JW, Khan NA, Gratama JW, van der Geest JN, Frens M, Benner R, Sillevis Smitt PA
Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurological syndromes.
J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1341-4
van der Bol JM, de Jong FA, van Schaik RH, Sparreboom A, van Fessem MA, van de Geijn FE, van Daele PL, Verweij J, Sleijfer S, Mathijssen RH
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.
Oncologist. 2010;15(10):1063-72
van der Bol JM, Mathijssen RH, Creemers GJ, Planting AS, Loos WJ, Wiemer EA, Friberg LE, Verweij J, Sparreboom A, de Jong FA
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Clin Cancer Res. 2010 Jan 15;16(2):736-42
van der Heide A, Veerbeek L, Swart S, van der Rijt C, van der Maas PJ, van Zuylen L
End-of-life decision making for cancer patients in different clinical settings and the impact of the LCP.
J Pain Symptom Manage. 2010 Jan;39(1):33-43
van Herpen CM, Eskens FA, de Jonge M, Desar I, Hooftman L, Bone EA, Timmer-Bonte JN, Verweij J
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
Br J Cancer. 2010 Oct 26;103(9):1362-8
van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA
MicroRNAs in ovarian cancer biology and therapy resistance.
Int J Biochem Cell Biol. 2010 Aug;42(8):1282-90
van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ, , Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.
Br J Surg. 2010 May;97(5):671-9
van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ,
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Ann Oncol. 2010 May;21(5):974-82
Veerbeek L, van de Poll-Franse LV, Bekkenk MW, Bergman W, Hoekstra HJ, Jansen-Landheer ML, Kruit WH, Mooi WJ, de Vries E, van der Rhee HJ
[Improved compliance with the 'Melanoma' treatment guideline].
Ned Tijdschr Geneeskd. 2010;154:A858
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, ,
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
N Engl J Med. 2010 Sep 2;363(10):943-53
Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
Ann Oncol. 2010 Jul;21(7):1472-81
Verweij J, Baker LH
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.
Eur J Cancer. 2010 Mar;46(5):863-8
Verweij J, Disis ML, Cannistra SA
Phase I studies of drug combinations.
J Clin Oncol. 2010 Oct 20;28(30):4545-6
Walker LC, Fredericksen ZS, Wang X, Tarrell R, Pankratz VS, Lindor NM, Beesley J, Healey S, Chen X, , Stoppa-Lyonnet D, Tirapo C, Giraud S, Mazoyer S, Muller D, Fricker JP, Delnatte C, , Schmutzler RK, Wappenschmidt B, Engel C, Schönbuchner I, Deissler H, Meindl A, Hogervorst FB, Verheus M, Hooning MJ, van den Ouweland AM, Nelen MR, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gerrits MM, Waisfisz Q, , Szabo CI, , Easton DF, Peock S, Cook M, Oliver CT, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Davidson R, Eccles D, Ong KR, Cook J, , Rebbeck T, Nathanson KL, Domchek SM, Singer CF, Gschwantler-Kaulich D, Dressler AC, Pfeiler G, Godwin AK, Heikkinen T, Nevanlinna H, Agnarsson BA, Caligo MA, Olsson H, Kristoffersson U, Liljegren A, Arver B, Karlsson P, Melin B, , Sinilnikova OM, McGuffog L, Antoniou AC, Chenevix-Trench G, Spurdle AB, Couch FJ
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.
Breast Cancer Res. 2010;12(6):R102
Wang X, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M, McGuffog L, Pharaoh PD, Ponder BA, Dunning AM, Peock S, Cook M, Oliver C, Frost D, , Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Houdayer C, , Hogervorst FB, Hooning MJ, Ligtenberg MJ, , Spurdle A, Chenevix-Trench G, , Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Domchek SM, Nathanson KL, Rebbeck TR, Singer CF, Gschwantler-Kaulich D, Dressler C, Fink A, Szabo CI, Zikan M, Foretova L, Claes K, Thomas G, Hoover RN, Hunter DJ, Chanock SJ, Easton DF, Antoniou AC, Couch FJ
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Hum Mol Genet. 2010 Jul 15;19(14):2886-97
Wasielewski M, Out AA, Vermeulen J, Nielsen M, van den Ouweland A, Tops CM, Wijnen JT, Vasen HF, Weiss MM, Klijn JG, Devilee P, Hes FJ, Schutte M
Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer.
Breast Cancer Res Treat. 2010 Dec;124(3):635-41
Wooldridge L, Clement M, Lissina A, Edwards ES, Ladell K, Ekeruche J, Hewitt RE, Laugel B, Gostick E, Cole DK, Debets R, Berrevoets C, Miles JJ, Burrows SR, Price DA, Sewell AK
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.
J Immunol. 2010 Apr 1;184(7):3357-66
Zubakov D, Boersma AW, Choi Y, van Kuijk PF, Wiemer EA, Kayser M
MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation.
Int J Legal Med. 2010 May;124(3):217-26